Author

Monica Balcells-Oliver

Institution: Vifor Pharma (Switzerland)

Observed institution: Vifor Pharma (Switzerland)

ORCID: 0009-0002-2924-7333

Observed ORCID: 0009-0002-2924-7333

OpenAlex ID: A5093977481

Treatment goals in ANCA-associated vasculitis: defining success in a new era

2024 · Federico Alberici, Martina Tedesco, et al. · Frontiers in Immunology · 11

Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial

2025 · Duvuru Geetha, Christian Pagnoux, et al. · Rheumatology · 10

Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmich et al

2024 · Joanna C Robson, Montserrat M Díaz Encarnación, et al. · Annals of the Rheumatic Diseases · 2

Evaluation of the Long-Term Safety of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the Real World (AvacoStar): Protocol for a Noninterventional Prospective Cohort Study

2026 · David R W Jayne, Raashid Luqmani, et al. · JMIR Research Protocols · 1

Avacopan Real-World Safety in Adults with ANCA-Associated Vasculitis: AvacoStar Interim Results

2026 · David R.W. Jayne, Raashid Ahmed Luqmani, et al. · Journal of the American Society of Nephrology

Baseline Characteristics of the First Patients in AvacoStar, a Real-World Study of Avacopan in ANCA-Associated Vasculitis

2024 · Achim Obergfell, David R.W. Jayne, et al. · Journal of the American Society of Nephrology

Works count: 6

Citation count: 24

H-index: 2

I10-index: 2